CRISPR Therapeutics shareholders elect new director, approve board size increase at 2025 AGM

CRISPR Therapeutics AG

New director Briggs W. Morrison, M.D. elected; board size maximum increased.
Binding votes on executive compensation approved with significant against votes (e.g., equity grant for execs: 31.8M for, 9.0M against).
Non-binding advisory vote on named executive officer compensation passed with 29.1M for vs 11.7M against.
Shareholders approved amendments to articles of association, effective June 6, 2025, subject to Swiss registration.
All director nominees re-elected; auditors Ernst & Young re-elected for FY2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CRISPR Therapeutics AG: Shareholders approved amendments to the Articles of Association, as described in the Proxy Statement, effective upon registration in the Commercial Register in Zug, Switzerland on or about June 6, 2025 (effective 2025-06-06).

Change: charter amendment
Effective: 2025-06-06

Exact text from the filing

On June 5, 2025, at the 2025 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of CRISPR Therapeutics AG (the “Company”) approved amendments to the articles of association of the Company (the “Articles of Association”) as described in the Company’s proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 16, 2025 (the “Proxy Statement”).

View on SEC.gov

Browse all governance changes →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-25-083799

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.